RS61933B1 - Lečenje bolesti kalem protiv domaćina kod transplantiranih pacijenata - Google Patents

Lečenje bolesti kalem protiv domaćina kod transplantiranih pacijenata

Info

Publication number
RS61933B1
RS61933B1 RS20210626A RSP20210626A RS61933B1 RS 61933 B1 RS61933 B1 RS 61933B1 RS 20210626 A RS20210626 A RS 20210626A RS P20210626 A RSP20210626 A RS P20210626A RS 61933 B1 RS61933 B1 RS 61933B1
Authority
RS
Serbia
Prior art keywords
compound
conditioning
use according
day
days
Prior art date
Application number
RS20210626A
Other languages
English (en)
Serbian (sr)
Inventor
Peter Gergely
Kazuhiko Kuriyama
Original Assignee
Priothera Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Priothera Ltd filed Critical Priothera Ltd
Publication of RS61933B1 publication Critical patent/RS61933B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01BSOIL WORKING IN AGRICULTURE OR FORESTRY; PARTS, DETAILS, OR ACCESSORIES OF AGRICULTURAL MACHINES OR IMPLEMENTS, IN GENERAL
    • A01B1/00Hand tools
    • A01B1/02Spades; Shovels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/145Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/664Amides of phosphorus acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/28Mercury; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/32Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/094Esters of phosphoric acids with arylalkanols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Environmental Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Soil Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RS20210626A 2013-02-20 2014-02-18 Lečenje bolesti kalem protiv domaćina kod transplantiranih pacijenata RS61933B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361766830P 2013-02-20 2013-02-20
PCT/IB2014/059067 WO2014128611A1 (en) 2013-02-20 2014-02-18 Treatment of graft versus host disease in transplant patients
EP14708330.7A EP2958624B1 (en) 2013-02-20 2014-02-18 Treatment of graft versus host disease in transplant patients

Publications (1)

Publication Number Publication Date
RS61933B1 true RS61933B1 (sr) 2021-07-30

Family

ID=50236228

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20210626A RS61933B1 (sr) 2013-02-20 2014-02-18 Lečenje bolesti kalem protiv domaćina kod transplantiranih pacijenata

Country Status (23)

Country Link
US (2) US20160000811A1 (enExample)
EP (1) EP2958624B1 (enExample)
JP (2) JP6441822B2 (enExample)
KR (1) KR102165514B1 (enExample)
CN (1) CN105007981B (enExample)
AU (1) AU2014220377B2 (enExample)
BR (1) BR112015019197A2 (enExample)
CA (1) CA2898565C (enExample)
CY (1) CY1124191T1 (enExample)
DK (1) DK2958624T3 (enExample)
EA (1) EA030783B1 (enExample)
ES (1) ES2873181T3 (enExample)
HR (1) HRP20210891T1 (enExample)
HU (1) HUE054330T2 (enExample)
LT (1) LT2958624T (enExample)
MX (1) MX369631B (enExample)
PL (1) PL2958624T3 (enExample)
PT (1) PT2958624T (enExample)
RS (1) RS61933B1 (enExample)
SI (1) SI2958624T1 (enExample)
SM (1) SMT202100334T1 (enExample)
TW (1) TWI648050B (enExample)
WO (1) WO2014128611A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018017134A2 (pt) * 2016-03-08 2019-01-15 Kyorin Seiyaku Kk tratamento de pacientes com transplante de célula-tronco hematopoiética
EP3831370A4 (en) * 2018-07-27 2022-04-27 Priothera Limited AGENT FOR INHIBITING THE RECURRENCE OF HEMATOLOGICAL MALIGNITY IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION
CN117177748A (zh) * 2020-11-04 2023-12-05 浩康生物系统公司 用于异基因造血干细胞移植的方法
AU2021424131A1 (en) 2021-01-28 2023-07-27 Priothera Limited Methods of treatment with s1p receptor modulators
EP4438037A1 (en) 2021-01-28 2024-10-02 Priothera SAS Methods of treatment with s1p receptor modulators
JP2025506506A (ja) 2022-02-16 2025-03-11 プリオセラ エスエーエス S1p受容体モジュレーターと組み合わせたcar細胞を用いた処置方法
EP4282407A1 (en) 2022-05-27 2023-11-29 Priothera SAS Treatment of cancer with s1p receptor agonists
WO2025109119A1 (en) 2023-11-22 2025-05-30 Priothera Sas Methods of treatment with multispecific antigen-binding proteins in combination with s1p receptor modulators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1011694A4 (en) * 1996-11-15 2000-11-15 Baxter Int TREATMENT FOR ALLOGENIC STEM CELL TRANSPLANTATION
US6383481B1 (en) 1998-03-30 2002-05-07 Japan Immunoresearch Laboratories Co., Ltd. Method for transplantation of hemopoietic stem cells
JPH11343242A (ja) * 1998-03-30 1999-12-14 Otsuka Pharmaceut Co Ltd 造血幹細胞移植用剤
AU2002332289B2 (en) * 2001-09-27 2007-05-10 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
US7482491B2 (en) * 2002-09-19 2009-01-27 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivative, addition salt thereof, and immunosuppressant
AU2005264431B2 (en) * 2004-07-16 2010-08-19 Kyorin Pharmaceutical Co., Ltd. Method of effectively using medicine and method concerning prevention of side effect
JP4966019B2 (ja) * 2005-01-06 2012-07-04 キッセイ薬品工業株式会社 慢性移植片対宿主症におけるドライアイの予防および治療剤
WO2011140170A1 (en) 2010-05-04 2011-11-10 Yeda Research And Development Co. Ltd. Immunotherapy using redirected allogeneic cells
AU2011249789B2 (en) 2010-05-06 2015-03-19 Novartis Ag Dosage regimen of diaryl sulfide derivatives

Also Published As

Publication number Publication date
TW201511751A (zh) 2015-04-01
TWI648050B (zh) 2019-01-21
MX2015010833A (es) 2016-07-08
AU2014220377A1 (en) 2015-08-06
US20160000811A1 (en) 2016-01-07
AU2014220377B2 (en) 2017-05-04
KR102165514B1 (ko) 2020-10-15
CA2898565A1 (en) 2014-08-28
WO2014128611A1 (en) 2014-08-28
JP6441822B2 (ja) 2018-12-19
JP2016509050A (ja) 2016-03-24
CN105007981A (zh) 2015-10-28
HRP20210891T1 (hr) 2021-07-23
PT2958624T (pt) 2021-06-11
JP2019059748A (ja) 2019-04-18
LT2958624T (lt) 2021-08-10
EA201591522A1 (ru) 2016-03-31
EA030783B1 (ru) 2018-09-28
SI2958624T1 (sl) 2021-07-30
PL2958624T3 (pl) 2021-10-04
US20180153911A1 (en) 2018-06-07
US11224604B2 (en) 2022-01-18
DK2958624T3 (da) 2021-06-07
ES2873181T3 (es) 2021-11-03
BR112015019197A2 (pt) 2017-07-18
CY1124191T1 (el) 2022-05-27
SMT202100334T1 (it) 2021-07-12
EP2958624A1 (en) 2015-12-30
CN105007981B (zh) 2020-07-21
JP6633170B2 (ja) 2020-01-22
CA2898565C (en) 2023-01-24
KR20150118149A (ko) 2015-10-21
EP2958624B1 (en) 2021-05-12
MX369631B (es) 2019-11-14
HUE054330T2 (hu) 2021-09-28

Similar Documents

Publication Publication Date Title
RS61933B1 (sr) Lečenje bolesti kalem protiv domaćina kod transplantiranih pacijenata
US20240293408A1 (en) Methods of treating and preventing graft versus host disease
CN105451750A (zh) 治疗人的实体肿瘤的诺氏梭菌
JP2020532555A (ja) ダントロレンを使用して神経薬暴露を治療する方法
CN112274509B (zh) 西达本胺联合bcl2抑制剂在双表达型b细胞淋巴瘤中的应用
EP3426279B1 (en) Treatment of hematopoietic stem cell transplant patients
US10058517B1 (en) Methods of treating acanthamoeba infection using apocynin
Hamed et al. P-067; Efficacy and Safety of Golimumab in Ulcerative Colitis: Experience From Two Large Boston Academic Hospitals
Speyer et al. DRES-19. SEX-BASED DIFFERENCES IN TUMOR RESPONSE TO (TARGETED) THERAPEUTICS: NUANCED SIGNALING MEDIATORS REVEAL TREATMENT OPPORTUNITIES
Bilgin et al. 277: Allogeneic hematopoietic cell transplantation in imatinib era: A single center comparative analysis of imatinib receiving patients to imatinib naive patients